TNXP: No AdCom Required for TNX-102 SL NDA…
TNXP READ THE FULL TNXP RESEARCH REPORT Business Update No Advisory Committee Meeting for TNX-102 SL NDA On March 24, 2025, ...
Investornewsbreaks Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) CEO To Present At 2025 Jones Trading Healthcare Conference
Tonix Pharmaceuticals (NASDAQ: TNXP) , a fully integrated biopharmaceutical company with marketed products and a robust development pipeline, announc ...
Tonix Pharmaceuticals to Present at the 2025 Jones Trading Healthcare and Innovation Conference
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biopharmaceutical company with marketed products and a ...
Tonix Pharma stock rises following TONIX ONE launch
Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, emphasized the company’s innovative efforts to improve patient access to necessary medications. He stated that TONIX ONE ...
Tonix Pharmaceuticals launches TONIX ONE digital platform
Tonix Pharmaceuticals (TNXP) announced the launch of TONIX ONE, a fully-integrated digital platform designed to help patients better understand ...
American Association of Individual Investors3d
Why Tonix Pharmaceuticals Holding Corp.’s (TNXP) Stock Is Down 11.27%
Tonix Pharmaceuticals Holding Corp.’s TNXP share price has dipped by 11.27%, which has investors questioning if this is right time to buy.
Biomednewsbreaks - Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Advances Non-Opioid Fibromyalgia Drug Toward FDA Decision
Tonix Pharmaceuticals (NASDAQ: TNXP) is gaining attention as it advances TNX-102 SL, a non-opioid investigational therapy for fibromyalgia, toward po ...